Did FDA safety warnings and CMS coverage restrictions improve guideline adherence for ESA use for patients with myelodysplastic syndromes?
Franklin Hendrick
No relevant relationships to disclose
Maria R. Baer
No relevant relationships to disclose
Steven Gore
Consultant or Advisory Role - GlaxoSmithKline; Novartis
Research Funding - GlaxoSmithKline; Novartis
Sheila Weiss Smith
No relevant relationships to disclose
Amy J. Davidoff
Consultant or Advisory Role - GlaxoSmithKline (I); Novartis (I)
Research Funding - GlaxoSmithKline; Novartis